Data monitoring committee (DMC)
A data monitoring committee (DMC), also called a data and safety monitoring board (DSMB) or independent data monitoring committee (IDMC), is a group of independent experts, typically clinicians and a statistician, appointed by the sponsor to review accumulating safety and, where relevant, efficacy data from an ongoing clinical trial and to recommend whether the trial should continue unchanged, be modified or be stopped. Its operation is described in a DMC charter, in line with the EMA guideline on data monitoring committees (2005) and FDA guidance (2006), and it is referenced in ICH E6 and E9.
DMCs are expected in trials with mortality or major morbidity endpoints, in vulnerable populations, in long-duration or adaptive trials, and wherever interim analyses may lead to early stopping for benefit, harm or futility. The DMC sees unblinded data prepared by an independent statistician, while the sponsor and investigators remain blinded.
The unblinded interim datasets are pseudonymised health data and are among the most sensitive information generated in a trial, both for participants and for the sponsor's commercial position. Access controls, confidentiality agreements, secure transfer to committee members (who may be located outside the EEA) and clear allocation of controller and processor roles for the independent statistical centre should be addressed in the charter and in the trial's DPIA.
No. A DMC generally provides independent recommendations about whether a trial should continue, change or stop; the sponsor remains responsible for deciding and acting within the applicable requirements. Define how recommendations are communicated and escalated in the committee charter, while protecting confidential interim results and the trial blind.
Request our booklet
See how we can help you via our comprehensive program,
set of tools and services.
